TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| IMMU Announces Positive Lupus Drug Results Douglas Cress submits: Immunomedics (IMMU) has become the second biopharmaceutical company in recent weeks to announce a successful trial of its lupus drug. The company’s lupus medication, epratuzumab, showed a 24.9% advantage over a placebo in a 12-week Phase IIb clinical trial. Shares in Immunomedics jumped 57 percent to its highest level in 5 years following the announcement. Five weeks ago, Human Genome Sciences (HGSI) became the first company to report positive Phase III data against lupus. The clinical success of its drug, Benlysta, caused shares in HGS to rise 277 percent in July. Shares in HGS dipped slightly following the announcement of Immunomedics’ results. It has recently been rumored that HGS will be bought out by pharmaceutical company GlaxoSmithKline (GSK), HGS’s partner in developing Benlysta. Both Benlysta and epretuzumab work by targeting the cell activity that leads to lupus.Complete Story » seekingalpha.com |
Stents Perform Well, Studies Show Stent heart devices from Abbott and Medtronic outperformed an older device from Boston Scientific in three-year data from two studies by better helping patients avoid serious events. online.wsj.com |
Medicare Vote Divides Democrats The Senate voted down a bill to prevent Medicare payment cuts to doctors. Democrats moved to stiffen antitrust laws on insurers. online.wsj.com |
Health-Care Haggling Heats Up Democratic leaders moved their health bill to the Senate floor, where issues including abortion and cost remain divisive for party members. online.wsj.com |
Healthy Entertaining Tips - Video AVOID THE BATTLE OF THE BULGE THIS HOLIDAY SEASON feedproxy.google.com |